Fushixiang Pharmaceutical (300497.SZ) announced its performance for the first half of the year, with a net loss attributable to shareholders of 6.91 million yuan, a decrease of 69.23%.

Wisdom Financial APP News, Fuxiang Pharmaceutical (300497.SZ) released its half-year report for 2025, with the company's operating income being 515 million yuan, a year-on-year decrease of 24.58%. The net loss attributable to shareholders of the listed company was 6.9112 million yuan, a year-on-year decrease of 69.23%. The net loss attributable to shareholders of the listed company excluding non-recurring gains and losses was 32.1798 million yuan, a year-on-year decrease of 34.91%. The basic loss per share was 0.01 yuan.